Clinical Trial Update: AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. [Phase 1, Phase 2]

View source ↗

Summary

This document describes a Phase 1/Phase 2 clinical trial evaluating AZD3470 as a monotherapy or in combination with other anticancer agents for hematologic mali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Hodgkin Lymphoma
• Lymphoma
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma
• Peripheral T-cell Lymphoma Not Otherwise Specified

Drugs mentioned

• AZD3470 (PRMT5 inhibitor)

Snippet

Sponsor: AstraZeneca | Conditions: Lymphoma, Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING